Local BCG therapy of superficial bladder tumours.
A total of 126 patients, whose superficial bladder tumours (Ta-Tl) had been removed by TUR, were subjected to local BCG therapy. Marked by frequent though mild side effects, they presented a significantly lower rate of tumour recurrence than the control group under exclusive TUR treatment. During a follow-up period of 3 years, 74% of the patients proved recurrence-free. BCG and Adriamycin were found largely similar in degree of effectiveness.
Kondás
J
J
Department of Urologic Surgery, Municipal Péterfy Sándor Street Hospital and Outpatient Clinic, Budapest, Hungary.
Szentgyörgyi
E
E
Szecsö
L
L
Kondér
G
G
D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine